Frederic (Rick) Bourke has over 50 years of experience in the world of science and biology. Rick is the founder and CEO of Immunolight, LLC. He and his team have spent the last 18 years developing groundbreaking technology that will shift how the world looks at treatments for cancer. In addition, Immunolight technology has countless industrial applications that will be gamechangers in areas such as: adhesives, solar, color and many others. 

Prior to starting Immunolight, Rick spent decades in biology, working with Lee Hood, Charles Cantor, Isidore Edelman and many others. He is the founder of Leukocyte Research and developer of Photopheresis. Photopheresis has become the standard of care for Cutaneous T-Cell Lymphoma and was sold to JNJ in 1982, becoming the company THERAKOS. Rick was also a key factor in the Human Genome Initiative, with Craig Venter and was the Chair of the scientific advisory board to Fisher Scientific. 

Rick received his BBA degree at the University of Michigan, and his MBA from Columbia University. He is also the co-founder and current co-owner of Dooney & Bourke, Inc (est. 1975).